In Phase II of covid19 clinical trails
https//clinicaltrails.gov/ct2/show/ntc04402957
From8K period ending 06/30/21
ARCH BIOPARTNERS INC.
Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended June 30, 2021 and 2020 (Unaudited - See Notice of No Auditor Review)
1. DESCRIPTION OF OPERATIONS
Arch Biopartners Inc. (the “Company”) is a portfolio based biotechnology company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. The Company works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
At present, the Company is focused on the clinical development of its lead drug candidate Metablok TM.
• Metablok TM - or ‘LSALT peptide’, has the potential to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys which often results in organ damage or failure, including in the case of sepsis and COVID-19;
The Company has three additional technology platforms in its portfolio under development:
• AB569 - a new drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily in the lungs, and wounds;
• Borg: Peptide-Solid Surface Interface - binding of proprietary peptides to solid metal and plastic surfaces to inhibit biofilm formation and reduce corrosion; and
• MetaMx TM - proprietary synthetic molecules that target brain tumour initiating cells and invasive glioma cells.
The Company owns, or has exclusive licensing rights on the intellectual property ("IP") emanating from the programs listed above.
The corporate headquarters are located in Toronto, Ontario.
